Panel Discussion: How to Know When a CDx & a Predictive Biomarker is Needed for a Drug

Time: 4:00 pm
day: Day One


  • Discussing criteria determining which drugs to progress for CDx selection to inform clinical strategy and investment plan
  • Changing requirements to implement a diagnostic in the early phase clinical trial Vs what’s needed for later approval
  • Engaging different arms of the business, to build trust for CDx development
  • Pre-empting bottlenecks in Dx development to de-risk investment